NCT04095351 Connective Tissue Diseases and Lung Manifestations
| NCT ID | NCT04095351 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University Innsbruck |
| Condition | Connective Tissue Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2019-12-09 |
| Primary Completion | 2021-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2019-12-09 with a primary completion date of 2021-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Despite a number of prospective studies already initiated in the past years, the current epidemiology and course of interstitial lung disease (ILD) and pulmonary hypertension (PH) in patients with connective tissue disease (CTD) is still not well defined, particularly regarding its prevalence, incidence and the management of a broad spectrum of disease presentations. Major challenges include the identification of patients with progressive disease, the appropriate time point of therapeutic intervention and the underlying driver of disease (inflammatory or pro-fibrotic stimulus or both?). To address these issues in Western Austria, a progressive registry of patients with CTD exploring routine clinical and pathophysiological characteristics of ILD and PH will be conducted. This multidisciplinary, prospective and observational registry aims to collect comprehensive clinical data on incidence, prevalence and course of disease regarding all PH and ILD presentations in a real-world setting.
Eligibility Criteria
Inclusion Criteria: * The inclusion criteria are adult patients (≥18 years) diagnosed with CTD with signed informed consent. Exclusion Criteria: * Exclusion criteria are patients with a serious co-morbidity interfering with the course of interstitial lung disease or pulmonary hypertension.
Contact & Investigator
Judith Löffler-Ragg, Prof. MD
PRINCIPAL INVESTIGATOR
Medical University Innsbruck, Department Internal Medicine
Frequently Asked Questions
Who can join the NCT04095351 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Connective Tissue Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04095351 currently recruiting?
Yes, NCT04095351 is actively recruiting participants. Contact the research team at magdalena.aichner@i-med.ac.at for enrollment information.
Where is the NCT04095351 trial being conducted?
This trial is being conducted at Innsbruck, Austria.
Who is sponsoring the NCT04095351 clinical trial?
NCT04095351 is sponsored by Medical University Innsbruck. The principal investigator is Judith Löffler-Ragg, Prof. MD at Medical University Innsbruck, Department Internal Medicine. The trial plans to enroll 120 participants.